Reply to L.B. Saltz [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - April 19, 2016 Category: Cancer & Oncology Authors: Mork, You, Vilar Tags: CORRESPONDENCE Source Type: research

Genetic Screening in All Young Patients With Colorectal Cancer? [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - April 19, 2016 Category: Cancer & Oncology Authors: Saltz Tags: CORRESPONDENCE Source Type: research

Compartmentalizing Cancer [ART OF ONCOLOGY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - April 19, 2016 Category: Cancer & Oncology Authors: Melton Tags: End of life issues, Emotions of the oncologist, All Art of Oncology Articles Source Type: research

International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment [SPECIAL ARTICLE]
Purpose The aim of the International Myeloma Working Group was to develop practical recommendations for the diagnosis and management of multiple myeloma–related renal impairment (RI). Methods Recommendations were based on published data through December 2015, and were developed using the system developed by the Grading of Recommendation, Assessment, Development, and Evaluation Working Group. Recommendations All patients with myeloma at diagnosis and at disease assessment should have serum creatinine, estimated glomerular filtration rate, and electrolytes measurements as well as free light chain, if available, and u...
Source: Journal of Clinical Oncology - April 19, 2016 Category: Cancer & Oncology Authors: Dimopoulos, Sonneveld, Leung, Merlini, Ludwig, Kastritis, Goldschmidt, Joshua, Orlowski, Powles, Vesole, Garderet, Einsele, Palumbo, Cavo, Richardson, Moreau, San Miguel, Rajkumar, Durie, Terpos Tags: Non-ASCO Guidelines SPECIAL ARTICLE Source Type: research

Accuracy of Adverse Event Ascertainment in Clinical Trials for Pediatric Acute Myeloid Leukemia [Pediatric Oncology]
This study sought to determine the accuracy of AE reporting for pediatric acute myeloid leukemia clinical trials and to test whether an external electronic data source can improve reporting. Methods Reported AEs were evaluated on two trials, Children’s Oncology Group AAML03P1 and AAML0531 arm B, with identical chemotherapy regimens but with different toxicity reporting requirements. Chart review for 12 AEs for patients enrolled in AAML0531 at 14 hospitals was the gold standard. The sensitivity and positive predictive values (PPV) of the AAML0531 AE report and AEs detected by review of Pediatric Health Information Sy...
Source: Journal of Clinical Oncology - April 19, 2016 Category: Cancer & Oncology Authors: Miller, Li, Kavcic, Troxel, Huang, Sung, Alonzo, Gerbing, Hall, Daves, Horton, Pulsipher, Pollard, Bagatell, Seif, Fisher, Luger, Gamis, Adamson, Aplenc Tags: Clinical Trials, Supportive Care, Epidemiology, Supportive Care, Acute Non-Lymphoblastic Leukemia/MDS/CML Pediatric Oncology Source Type: research

Surgical Proficiency Gain and Survival After Esophagectomy for Cancer [Surgical Oncology]
Purpose We aimed to identify the presence and length of esophagectomy proficiency gain curves in terms of short- and long-term mortality for esophageal cancer. Patients and Methods Patients who underwent esophagectomy for esophageal cancer between 1987 and 2010 with follow-up until 2014 were identified from a well-established, population-based, nationwide Swedish cohort study. Proficiency gain curves were created by using risk-adjusted cumulative sum analysis for 30-day, 90-day, 1-year, 3-year, and 5-year all-cause and disease-specific mortality measures. Similarly, the proficiency gain curves for lymph node harvest, rese...
Source: Journal of Clinical Oncology - April 19, 2016 Category: Cancer & Oncology Authors: Markar, Mackenzie, Lagergren, Hanna, Lagergren Tags: Surgery Surgical Oncology Source Type: research

Patient-Reported Outcomes After Choice for Contralateral Prophylactic Mastectomy [Surgical Oncology]
Purpose The rate of contralateral prophylactic mastectomies (CPMs) continues to rise, although there is little evidence to support improvement in quality of life (QOL) with CPM. We sought to ascertain whether patient-reported outcomes and, more specifically, QOL differed according to receipt of CPM. Methods Volunteers recruited from the Army of Women with a history of breast cancer surgery took an electronically administered survey, which included the BREAST-Q, a well-validated breast surgery outcomes patient-reporting tool, and demographic and treatment-related questions. Descriptive statistics, hypothesis testing, and r...
Source: Journal of Clinical Oncology - April 19, 2016 Category: Cancer & Oncology Authors: Hwang, Locklear, Rushing, Samsa, Abernethy, Hyslop, Atisha Tags: Surgery, Quality of Life, Surgical Oncology Source Type: research

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab [Immunotherapy]
Conclusion Atypical responses were observed in patients with melanoma treated with pembrolizumab. Based on survival analysis, conventional RECIST might underestimate the benefit of pembrolizumab in approximately 15% of patients; modified criteria that permit treatment beyond initial progression per RECIST v1.1 might prevent premature cessation of treatment. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - April 19, 2016 Category: Cancer & Oncology Authors: Hodi, Hwu, Kefford, Weber, Daud, Hamid, Patnaik, Ribas, Robert, Gangadhar, Joshua, Hersey, Dronca, Joseph, Hille, Xue, Li, Kang, Ebbinghaus, Perrone, Wolchok Tags: Chemotherapy, CT Immunotherapy Source Type: research

Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial [Clinical Trials]
Conclusion The addition of ramucirumab to docetaxel met the prespecified efficacy end point for prolonging PFS in patients with locally advanced or metastatic urothelial carcinoma receiving second-line treatment and warrants further investigation in the phase III setting. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - April 19, 2016 Category: Cancer & Oncology Authors: Petrylak, Tagawa, Kohli, Eisen, Canil, Sridhar, Spira, Yu, Burke, Shaffer, Pan, Kim, Aragon-Ching, Quinn, Vogelzang, Tang, Zhang, Cavanaugh, Gao, Kauh, Walgren, Chi Tags: Chemotherapy Clinical Trials Source Type: research

Pulmonary Function in Patients With Germ Cell Cancer Treated With Bleomycin, Etoposide, and Cisplatin [Urologic Oncology]
Conclusion After 5 years of follow-up, pulmonary impairment in patients with germ cell cancer who were treated with BEP was limited. Exceptions were patients treated with pulmonary surgery, those who suffered pulmonary embolism, and those in the IGCCCG poor prognostic group. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - April 19, 2016 Category: Cancer & Oncology Authors: Lauritsen, Kier, Bandak, Mortensen, Thomsen, Mortensen, Daugaard Tags: Chemotherapy Urologic Oncology Source Type: research

Detection of Occult Micrometastases in Patients With Clinical Stage I Non-Small-Cell Lung Cancer: A Prospective Analysis of Mature Results of CALGB 9761 (Alliance) [Thoracic Oncology]
Conclusion NSCLC tumor markers can be detected in histologically negative LNs by AE1/AE3 IHC and carcinoembryonic antigen RT-PCR. In this prospective, multi-institutional trial, the presence of OM by IHC staining in N2 LNs of patients with NSCLC correlated with decreased OS. The clinical significance of this warrants further investigation. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - April 19, 2016 Category: Cancer & Oncology Authors: Martin, DCunha, Wang, Herzan, Gu, Abraham, Demmy, Detterbeck, Groth, Harpole, Krasna, Kernstine, Kohman, Patterson, Sugarbaker, Vollmer, Maddaus, Kratzke Tags: Clinical Trials, Diagnosis & Staging, Surgery, Pathology Thoracic Oncology Source Type: research

Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study [Thoracic Oncology]
Conclusion In elderly patients with advanced NSCLC, treatment allocation on the basis of CGA failed to improve the TFFS or OS but slightly reduced treatment toxicity. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - April 19, 2016 Category: Cancer & Oncology Authors: Corre, Greillier, Le Caer, Audigier-Valette, Baize, Berard, Falchero, Monnet, Dansin, Vergnenegre, Marcq, Decroisette, Auliac, Bota, Lamy, Massuti, Dujon, Perol, Daures, Descourt, Lena, Plassot, Chouaid Tags: Geriatric Oncology, Chemotherapy Thoracic Oncology Source Type: research

Evolution of Randomized Trials in Advanced/Metastatic Soft Tissue Sarcoma: End Point Selection, Surrogacy, and Quality of Reporting [Sarcomas]
Conclusion In advanced STS, PFS and RR seem to be appropriate surrogates for OS. There is poor correlation between OS and both 3moPFS and 6moPFS. As such, caution is urged with the use of these as primary end points in randomized STS trials. The quality of toxicity reporting and interpretation of results is suboptimal. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - April 19, 2016 Category: Cancer & Oncology Authors: Zer, Prince, Amir, Abdul Razak Tags: Chemotherapy Sarcomas Source Type: research

Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer [Genetic Testing for Cancer]
Purpose Testing for germline mutations in BRCA1/2 is standard for select patients with breast cancer to guide clinical management. Next-generation sequencing (NGS) allows testing for mutations in additional breast cancer predisposition genes. The frequency of germline mutations detected by using NGS has been reported in patients with breast cancer who were referred for BRCA1/2 testing or with triple-negative breast cancer. We assessed the frequency and predictors of mutations in 25 cancer predisposition genes, including BRCA1/2, in a sequential series of patients with breast cancer at an academic institution to examine the...
Source: Journal of Clinical Oncology - April 19, 2016 Category: Cancer & Oncology Authors: Tung, Lin, Kidd, Allen, Singh, Wenstrup, Hartman, Winer, Garber Tags: Epidemiology, Genetic epidemiology Genetic Testing for Cancer Source Type: research

Panel Testing for Familial Breast Cancer: Calibrating the Tension Between Research and Clinical Care [Genetic Testing for Cancer]
Conclusion The frequency of mutations in most breast cancer panel genes among individuals selected for possible hereditary breast cancer is low and, in many cases, similar or even lower than that observed among cancer-free population controls. Although multigene panels can significantly aid in cancer risk management and expedite clinical translation of new genes, they equally have the potential to provide clinical misinformation and harm at the individual level if the data are not interpreted cautiously. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - April 19, 2016 Category: Cancer & Oncology Authors: Thompson, Rowley, Li, McInerny, Devereux, Wong-Brown, Trainer, Mitchell, Scott, James, Campbell Tags: Epidemiology Genetic Testing for Cancer Source Type: research

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction [Rapid Communication]
Purpose There is currently no standard treatment strategy for patients with advanced metastatic gastric cancer experiencing progression after two or more lines of chemotherapy. We assessed the efficacy and safety of apatinib, a novel vascular endothelial growth factor receptor 2 tyrosine kinase inhibitor, in patients with advanced gastric or gastroesophageal junction adenocarcinoma for whom at least two lines of prior chemotherapy had failed. Patients and Methods This was a randomized, double-blind, placebo-controlled phase III trial. Patients from 32 centers in China with advanced gastric or gastroesophageal junction ade...
Source: Journal of Clinical Oncology - April 19, 2016 Category: Cancer & Oncology Authors: Li, Qin, Xu, Xiong, Wu, Bai, Liu, Tong, Liu, Xu, Wang, Wang, Ouyang, Yang, Ba, Liang, Lin, Luo, Zheng, Wang, Sun, Wang, Zheng, Guo, Wu, Xu, Yang, Zhang, Cheng, Wang, Chen, Fan, Sun, Yu Tags: Chemotherapy, Rapid Communications, Rapid Communications Source Type: research

Re-Examining the Role of Radiation Therapy for Diffuse Large B-Cell Lymphoma in the Modern Era [COMMENTS AND CONTROVERSIES]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - April 19, 2016 Category: Cancer & Oncology Authors: Ng, Dabaja, Hoppe, Illidge, Yahalom Tags: Radiation, Combined Modality COMMENTS AND CONTROVERSIES Source Type: research

Optimizing Treatment Risk and Benefit for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Right Treatment for the Right Patient [ONCOLOGY GRAND ROUNDS]
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors’ suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice. A 78-year-old woman with a 40-pack-year smoking history has been referred for treatment of advanced non&n...
Source: Journal of Clinical Oncology - April 19, 2016 Category: Cancer & Oncology Authors: Presley, Gross, Lilenbaum Tags: Oncology Grand Rounds Source Type: research

Surrogate End Points and Their Validation in Oncology Clinical Trials [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - April 19, 2016 Category: Cancer & Oncology Authors: Zhao Tags: Clinical Trials EDITORIALS Source Type: research

Panel Testing Is Not a Panacea [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - April 19, 2016 Category: Cancer & Oncology Authors: Axilbund Tags: EDITORIALS Source Type: research

Targeting the Vascular Endothelial Growth Factor Pathway in Gastric Cancer: A Hit or a Miss? [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - April 19, 2016 Category: Cancer & Oncology Authors: Ilson Tags: Chemotherapy EDITORIALS Source Type: research

Advertising [Oncology Career Center]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - April 19, 2016 Category: Cancer & Oncology Tags: Oncology Career Center Source Type: research

Positron Emission Tomography-Computed Tomography Imaging of a Patient With Several Myeloid Sarcomas With FLT3-ITD and NPM1 Mutations [DIAGNOSIS IN ONCOLOGY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - April 19, 2016 Category: Cancer & Oncology Authors: von Keudell, Larson Tags: Leukemia, Diagnosis & Staging, Chemotherapy, Combined Therapy, Biological Therapy, Biology & Immunology, Translational Oncology, Nuclear Medicine DIAGNOSIS IN ONCOLOGY Source Type: research

Hypoglycemia Caused by Recurrent Renal Cell Carcinoma As Result of Production of High Molecular Weight Insulin-Like Growth Factor 2 [DIAGNOSIS IN ONCOLOGY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - April 19, 2016 Category: Cancer & Oncology Authors: Kimura, Mitsuzuka, Yamada, Kaiho, Watanabe, Ikeda, Chiba, Arai Tags: DIAGNOSIS IN ONCOLOGY Source Type: research

Successful Treatment of Relapsed Acute Myeloid Leukemia Without Chemotherapy [DIAGNOSIS IN ONCOLOGY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - April 19, 2016 Category: Cancer & Oncology Authors: Tang, Song, Sun, Zhu, Ruan, Wu Tags: Leukemia DIAGNOSIS IN ONCOLOGY Source Type: research

Erratum [erratum]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - April 12, 2016 Category: Cancer & Oncology Tags: ERRATUM Source Type: research

Multiple Dimensions of Value: Evaluative Frameworks for New Cancer Therapies [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - April 12, 2016 Category: Cancer & Oncology Authors: Cheung, Sabharwal, Chambers, Han, Sabarre, Chan Tags: CORRESPONDENCE Source Type: research

Reply to A.J. Olszewski et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - April 12, 2016 Category: Cancer & Oncology Authors: Vargo, Beriwal Tags: CORRESPONDENCE Source Type: research

Survival Claims From Observational Data on Cancer Therapy [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - April 12, 2016 Category: Cancer & Oncology Authors: Olszewski, Falah, Castillo Tags: CORRESPONDENCE Source Type: research

Reply to S.A. Rum et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - April 12, 2016 Category: Cancer & Oncology Authors: Jagsi, Walter Tags: CORRESPONDENCE Source Type: research

Instituting and Teaching Ethical Standards for Grateful Patient Fundraising [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - April 12, 2016 Category: Cancer & Oncology Authors: Rum, Wheeler, Wright Tags: CORRESPONDENCE Source Type: research

Reply to F.C.M. Cananzi et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - April 12, 2016 Category: Cancer & Oncology Authors: Park, Kang Tags: CORRESPONDENCE Source Type: research

Chemoradiotherapy in Gastric Cancer: A Door Ajar [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - April 12, 2016 Category: Cancer & Oncology Authors: Cananzi, Biondi, Quagliuolo, Rausei Tags: CORRESPONDENCE Source Type: research

White Knuckling [ART OF ONCOLOGY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - April 12, 2016 Category: Cancer & Oncology Authors: Rayson Tags: Emotions of the oncologist, All Art of Oncology Articles Source Type: research

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3 [SPECIAL ARTICLE]
Conclusion PCWG3 moves drug development closer to unmet needs in clinical practice by focusing on disease manifestations most likely to affect prognosis adversely for therapeutics tested in both nonmetastatic and metastatic CRPC populations. Consultation with regulatory authorities is recommended if a trial is intended to seek support for drug approval. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - April 12, 2016 Category: Cancer & Oncology Authors: Scher, Morris, Stadler, Higano, Basch, Fizazi, Antonarakis, Beer, Carducci, Chi, Corn, de Bono, Dreicer, George, Heath, Hussain, Kelly, Liu, Logothetis, Nanus, Stein, Rathkopf, Slovin, Ryan, Sartor, Small, Smith, Sternberg, Taplin, Wilding, Nelson, Schwar Tags: Systemic Therapy, Combined Modality Therapy SPECIAL ARTICLE Source Type: research

Case Example of Dose Optimization Using Data From Bortezomib Dose-Finding Clinical Trials [Statistical Analysis]
Conclusions When considering the entire course of treatment, the approved bortezomib dose exceeds the conventional ceiling DLT rate of 20% to 33%. Retrospective analysis of trial data provides an opportunity for dose optimization of MTAs. Future dose-finding studies of MTAs should take into account late-onset toxicities to ensure that a tolerable dose is identified for future efficacy and comparative trials. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - April 12, 2016 Category: Cancer & Oncology Authors: Lee, Backenroth, Cheung, Hershman, Vulih, Anderson, Ivy, Minasian Tags: Clinical Trials, Phase I and Clinical Pharmacology, Statistics in Oncology Statistical Analysis Source Type: research

Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network [Hematologic Malignancy]
Purpose Mantle-cell lymphoma (MCL) is a rather aggressive B-cell malignancy whose considerable variability of individual outcome is associated with clinical characteristics (Mantle Cell Lymphoma International Prognostic Index [MIPI]). The Ki-67 index is a strong independent prognostic factor; however, the biologic MIPI (MIPI-b) distinguishes only two groups, which does not appropriately depict the clinical heterogeneity. By using the cohort from the European MCL Younger and MCL Elderly trials, we aimed to evaluate the additional prognostic impact of cytology and growth pattern and to improve risk stratification with the Ki...
Source: Journal of Clinical Oncology - April 12, 2016 Category: Cancer & Oncology Authors: Hoster, Rosenwald, Berger, Bernd, Hartmann, Loddenkemper, Barth, Brousse, Pileri, Rymkiewicz, Kodet, Stilgenbauer, Forstpointner, Thieblemont, Hallek, Coiffier, Vehling-Kaiser, Bouabdallah, Kanz, Pfreundschuh, Schmidt, Ribrag, Hiddemann, Unterhalt, Kluin- Tags: Risk factors, Diagnosis & Staging, Chemotherapy, Biology & Immunology Hematologic Malignancy Source Type: research

Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study [Hematologic Malignancy]
Conclusion Patients with advanced-stage Hodgkin lymphoma for whom treatment was at high risk of failing appear to benefit from early treatment intensification with autologous transplantation, as indicated by the possibility of successful salvage treatment in more than 70% of PET2-positive patients through obtaining the same 2-year progression-free survival as the PET2-negative subgroup. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - April 12, 2016 Category: Cancer & Oncology Authors: Zinzani, Broccoli, Gioia, Castagnoli, Ciccone, Evangelista, Santoro, Ricardi, Bonfichi, Brusamolino, Rossi, Anastasia, Zaja, Vitolo, Pavone, Pulsoni, Rigacci, Gaidano, Stelitano, Salvi, Rusconi, Tani, Freilone, Pregno, Borsatti, Sacchetti, Argnani, Levis Tags: Combined Modality Hematologic Malignancy Source Type: research

Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial [Pediatric Oncology]
Conclusion Alisertib 60 mg/m2 per dose for 7 days is tolerable with a standard irinotecan and temozolomide backbone and has promising response and progression-free survival rates. A phase II trial of this regimen is ongoing. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - April 12, 2016 Category: Cancer & Oncology Authors: DuBois, Marachelian, Fox, Kudgus, Reid, Groshen, Malvar, Bagatell, Wagner, Maris, Hawkins, Courtier, Lai, Goodarzian, Shimada, Czarnecki, Tsao-Wei, Matthay, Mosse Tags: Neuroblastoma, Developmental Therapeutics & Pharmacology Pediatric Oncology Source Type: research

Long-Term Neurocognitive Functioning and Social Attainment in Adult Survivors of Pediatric CNS Tumors: Results From the St Jude Lifetime Cohort Study [Health Services and Outcomes]
Conclusion Survivors of pediatric CNS tumors are at risk of severe neurocognitive impairment in adulthood. The prevalence of severe impairment is greater than expected in the general population, even in the absence of CRT, and is associated with disrupted attainment of adult social milestones. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - April 12, 2016 Category: Cancer & Oncology Authors: Brinkman, Krasin, Liu, Armstrong, Ojha, Sadighi, Gupta, Kimberg, Srivastava, Merchant, Gajjar, Robison, Hudson, Krull Tags: Long Term Survival & Late Effects, CNS Tumors Health Services and Outcomes Source Type: research

Morbidity and Mortality of Laparoscopic Versus Open D2 Distal Gastrectomy for Advanced Gastric Cancer: A Randomized Controlled Trial [Gastrointestinal Cancer]
Conclusion Experienced surgeons can safely perform LG with D2 lymphadenectomy for AGC. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - April 12, 2016 Category: Cancer & Oncology Authors: Hu, Huang, Sun, Su, Cao, Hu, Xue, Suo, Tao, He, Wei, Ying, Hu, Du, Chen, Liu, Zheng, Liu, Yu, Li, Zhao, Chen, Wang, Li, Xing, Li Tags: Surgery Gastrointestinal Cancer Source Type: research

Associations Between Serum Vitamin D and Adverse Pathology in Men Undergoing Radical Prostatectomy [Urologic Oncology]
Conclusion Insufficiency/deficiency of serum 25-OH D is associated with increased odds of adverse pathology in men with localized disease undergoing radical prostatectomy. Serum 25-OH D may serve as a useful biomarker in prostate cancer aggressiveness, which deserves continued study. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - April 12, 2016 Category: Cancer & Oncology Authors: Nyame, Murphy, Bowen, Jordan, Batai, Dixon, Hollowell, Kielb, Meeks, Gann, Macias, Kajdacsy-Balla, Catalona, Kittles Tags: Molecular epidemiology, Diagnosis & Staging, Translational Oncology Urologic Oncology Source Type: research

Loss of Muscle Mass During Chemotherapy Is Predictive for Poor Survival of Patients With Metastatic Colorectal Cancer [Palliative and Supportive Care]
Purpose Low muscle mass is present in approximately 40% of patients with metastatic colorectal cancer (mCRC) and may be associated with poor outcome. We studied change in skeletal muscle during palliative chemotherapy in patients with mCRC and its association with treatment modifications and overall survival. Patients and Methods In 67 patients with mCRC (mean age ± standard deviation, 66.4 ± 10.6 years; 63% male), muscle area (square centimeters) was assessed using computed tomography scans of the third lumbar vertebra before and during palliative chemotherapy. Treatment modifications resulting from toxicit...
Source: Journal of Clinical Oncology - April 12, 2016 Category: Cancer & Oncology Authors: Blauwhoff-Buskermolen, Versteeg, de van der Schueren, den Braver, Berkhof, Langius, Verheul Tags: Quality of Life, Supportive Care Palliative and Supportive Care Source Type: research

Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma [Melanoma]
Conclusion The combination of TriMixDC-MEL and ipilimumab is tolerable and results in an encouraging rate of highly durable tumor responses in patients with pretreated advanced melanoma. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - April 12, 2016 Category: Cancer & Oncology Authors: Wilgenhof, Corthals, Heirman, van Baren, Lucas, Kvistborg, Thielemans, Neyns Tags: Combined Modality Melanoma Source Type: research

Trends in Health-Related Quality of Life After a Diagnosis of Ductal Carcinoma In Situ [Epidemiology]
The objective of this study was to assess long-term QoL in DCIS survivors in relation to age at diagnosis, time since diagnosis, and treatments received. Methods We assessed physical and mental measures of health-related QoL in 1,604 patients with DCIS diagnosed in 1997 to 2006 with up to four follow-up interviews. We further compared baseline QoL to 1,055 control patients without DCIS. QoL was measured using the validated Medical Outcomes Study Short Form 36 Health Status Survey questionnaire. Among patients with DCIS, we examined trends in QoL over time since diagnosis using generalized linear regression models, adjusti...
Source: Journal of Clinical Oncology - April 12, 2016 Category: Cancer & Oncology Authors: Hart, Sprague, Lakoski, Hampton, Newcomb, Gangnon, Trentham-Dietz Tags: Epidemiology, Population and observational studies (SEER, WHI observational, etc.), Quality of Life Source Type: research

Cigarette Smoking Before and After Breast Cancer Diagnosis: Mortality From Breast Cancer and Smoking-Related Diseases [Breast Cancer]
Conclusion Smoking before or after diagnosis was associated with a higher mortality from breast cancer and several other causes. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - April 12, 2016 Category: Cancer & Oncology Authors: Passarelli, Newcomb, Hampton, Trentham-Dietz, Titus, Egan, Baron, Willett Tags: Epidemiology, Behavioral and Lifestyle Risk Factors, Population and observational studies (SEER, WHI observational, etc.) Breast Cancer Source Type: research

Influence of the Acidic Beverage Cola on the Absorption of Erlotinib in Patients With Non-Small-Cell Lung Cancer [Thoracic Oncology]
Conclusion Cola intake led to a clinically relevant and statistically significant increase in the bioavailability of erlotinib during esomeprazole treatment. In patients not treated with the PPI, the effects of cola were marginal. These findings can be used to optimize the management of drug-drug interactions between PPIs and erlotinib. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - April 12, 2016 Category: Cancer & Oncology Authors: van Leeuwen, Peric, Hussaarts, Kienhuis, IJzerman, de Bruijn, van der Leest, Codrington, Kloover, van der Holt, Aerts, van Gelder, Mathijssen Tags: Translational Oncology, Chemotherapy, Phase I and Clinical Pharmacology Thoracic Oncology Source Type: research

Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab [Rapid Communication]
Conclusion p16 status was strongly prognostic for patients with OPC. The data suggest that the addition of cetuximab to RT improved clinical outcomes regardless of p16 or HPV status versus RT alone. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - April 12, 2016 Category: Cancer & Oncology Authors: Rosenthal, Harari, Giralt, Bell, Raben, Liu, Schulten, Ang, Bonner Tags: Rapid Communications, Combined Modality, Rapid Communications Source Type: research

Should the Benefit of Adjuvant Chemotherapy in Colon Cancer Be Re-Evaluated? [COMMENTS AND CONTROVERSIES]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - April 12, 2016 Category: Cancer & Oncology Authors: Pahlman, Hohenberger, Matzel, Sugihara, Quirke, Glimelius Tags: Chemotherapy COMMENTS AND CONTROVERSIES Source Type: research

Importance of Smoking Cessation to Reduce Breast Cancer Mortality [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - April 12, 2016 Category: Cancer & Oncology Authors: Parker, Pierce Tags: EDITORIALS Source Type: research